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Eolue dore regimene of recombinant tierue pleeminogen 
activator (rt=PA) seem both effective and convenient. We 
treated 59 pte (45 male, 14 female, mean age 58.5 yeare, 
range 29-75) presenting within 6 hours of a first myo- 
cardial infarction (24 anterior, 35 inferior) with 2 
intravenoue (IV) bolueee of rt-PA 30 minutes apart. 
Treatment regimen@ were Group (Gp) A 20/5O mg, Gp B SO/20 
mg and Gp C SO/SO q. All pte received 150 mg oral 
aspirin prior to treatment and then daily. IV heparin 
infusion was commenced 90 minutee after the firet bolus. 
Mean (*SD) time from onset of symptoms to treatment was 
l4S~f7l)minutes. At 90 minutee from the first bolus 
infarct related coronary artery patency (TIM1 2 or 3) was 
Gp A: 15120 (75x1, Gp B: 14/20 (70%) and Gp C: 17/19(90X). 
At 90 minute8 fibrinogen levels (n-30) for Gpe A,B and C 
were 15.5, 9.3 and 5.2% and factor V; 16.9, 22.3 and 
14.6% and plaeminogen; 32.8, 54 and 20% of baseline 
rerpectively. Thus exteneive syetemic plaeminogen 
activation occurred which appeared to mirror patency. 
No major bleeding complications occurred. There were 4 
pts with re-occlueion within 24 hours of rt-PA. Three 
ptr (5%) died. Treatment with 2 bolusee of rt-PA (SO/SO 
m8) rafely achieve8 high patency rates with eignificant 
rheologlcal effect6 which may promote reperfueion. 
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To compare the strategy of d&t FTCA vs. intravenous streatoklnase 
(IVSK)?or treatment Gf patients (pts) with acute myocardial hfarction 
(AM), 100 pts with less than 6 hrs chest pain and ST segment 
elevation were randomized to either treaunent IVSK was given as 1.2 
MU/lhr and all pts received intravenous heparin and PO aspirin. 
Cardiac catheterization was performed in PTa pts upon admission 
and a1 48hrs, and was performed in IVSK its at 48hr. Infarct artefv 
patency a1 48hrs and*LV ejection fracti;n (EF) prior to hospit; 
discharge were the primary study end incs. 
Pt Characteristics r 2 
Age (yrs) 
W\lk.$5 ) PTCA (n=SO) 
ns 
~Nga.l$ 
54 
ns 
ii&9 
ns 17 
;lTTtment (min) I S&k90 0.005 2WlOO 
Patency (90 min) -- SW 
Patency (48 hr) 40/50 (80%) ns 
Recurrent &hernia (a) i (10%) ns 
Transfusion22U (%) ns 
LVEF(%) - - 
M0-w (%I 
CONCLUSIONS: Thus, the equivalent re”ssults of these 2 strategies 
would suggest: 1) Intravenous thrombolysis is preferred over PTCA 
for most patients because of the time delay and increased 
PXA and 2) PTCA may quite rationally be applied when 
bleeding is high and reperfusion therapy is okrwise indicated. 
